CLINICAL TRIAL / NCT05682170

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

  • Interventional
  • Recruiting
  • NCT05682170

A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor ZN-c3 in Subjects With Acute Myeloid Leukemia

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia (AML).